John Roop - Anixa Biosciences Senior Engineering
| ANIX Stock | USD 2.81 0.13 4.85% |
Executive
John Roop is Senior Engineering of Anixa Biosciences
| Age | 75 |
| Address | 3150 Almaden Expressway, San Jose, CA, United States, 95118 |
| Phone | 408 708 9808 |
| Web | https://www.anixa.com |
Anixa Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.367) % which means that it has lost $0.367 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.601) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2025. Return On Capital Employed is likely to drop to -0.87 in 2025. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 250.2 K in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| BSc MD | Aerovate Therapeutics | N/A | |
| William CPA | Annovis Bio | 60 | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Bruce MD | Immunome | 61 | |
| Matteo MD | Cue Biopharma | 56 | |
| Melissa Gaines | Annovis Bio | N/A | |
| Rivi Levari | PolyPid | N/A | |
| Tim Smith | Pmv Pharmaceuticals | N/A | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Lucinda Warren | Cue Biopharma | N/A | |
| Katharine CPA | Acrivon Therapeutics, Common | N/A | |
| Gopal MBBS | Rezolute | N/A | |
| Michael Carulli | Pmv Pharmaceuticals | 51 | |
| Vince Hernandez | AN2 Therapeutics | N/A | |
| Marc MD | Pmv Pharmaceuticals | N/A | |
| Jonny Missulawin | PolyPid | 38 | |
| Ami Knoefler | Adagene | N/A | |
| David MD | Mineralys Therapeutics, Common | 70 | |
| Robert Lapetina | Immunome | 49 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 |
Anixa Biosciences Leadership Team
Elected by the shareholders, the Anixa Biosciences' board of directors comprises two types of representatives: Anixa Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anixa. The board's role is to monitor Anixa Biosciences' management team and ensure that shareholders' interests are well served. Anixa Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anixa Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amit Kumar, Chairman of the Board and Presidentident, CEO | ||
| John Roop, Senior Engineering | ||
| Pamela Garzone, Chief Officer | ||
| Thomas Schlumpberger, Ex Diagnostics |
Anixa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anixa Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 69.26 M | ||||
| Shares Outstanding | 32.2 M | ||||
| Shares Owned By Insiders | 5.29 % | ||||
| Shares Owned By Institutions | 18.29 % | ||||
| Number Of Shares Shorted | 402.86 K | ||||
| Price To Earning | (51.83) X | ||||
| Price To Book | 4.83 X | ||||
| Price To Sales | 481.54 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.